Haemonetics Statistics
Total Valuation
Haemonetics has a market cap or net worth of $3.79 billion. The enterprise value is $4.80 billion.
| Market Cap | 3.79B |
| Enterprise Value | 4.80B |
Important Dates
The next estimated earnings date is Thursday, February 6, 2025, before market open.
| Earnings Date | Feb 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Haemonetics has 50.22 million shares outstanding. The number of shares has increased by 0.23% in one year.
| Current Share Class | 50.22M |
| Shares Outstanding | 50.22M |
| Shares Change (YoY) | +0.23% |
| Shares Change (QoQ) | -0.63% |
| Owned by Insiders (%) | 0.94% |
| Owned by Institutions (%) | 112.15% |
| Float | 49.72M |
Valuation Ratios
The trailing PE ratio is 31.30 and the forward PE ratio is 15.37. Haemonetics's PEG ratio is 1.10.
| PE Ratio | 31.30 |
| Forward PE | 15.37 |
| PS Ratio | 2.82 |
| Forward PS | 2.64 |
| PB Ratio | 4.32 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 121.75 |
| P/OCF Ratio | 44.61 |
| PEG Ratio | 1.10 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.41, with an EV/FCF ratio of 154.36.
| EV / Earnings | 38.80 |
| EV / Sales | 3.53 |
| EV / EBITDA | 14.41 |
| EV / EBIT | 20.66 |
| EV / FCF | 154.36 |
Financial Position
The company has a current ratio of 3.49, with a Debt / Equity ratio of 1.50.
| Current Ratio | 3.49 |
| Quick Ratio | 1.87 |
| Debt / Equity | 1.50 |
| Debt / EBITDA | 3.82 |
| Debt / FCF | 42.25 |
| Interest Coverage | 14.89 |
Financial Efficiency
Return on equity (ROE) is 13.97% and return on invested capital (ROIC) is 7.55%.
| Return on Equity (ROE) | 13.97% |
| Return on Assets (ROA) | 6.41% |
| Return on Capital (ROIC) | 7.55% |
| Revenue Per Employee | $372,224 |
| Profits Per Employee | $33,856 |
| Employee Count | 3,657 |
| Asset Turnover | 0.60 |
| Inventory Turnover | 1.82 |
Taxes
In the past 12 months, Haemonetics has paid $35.05 million in taxes.
| Income Tax | 35.05M |
| Effective Tax Rate | 22.06% |
Stock Price Statistics
The stock price has decreased by -14.09% in the last 52 weeks. The beta is 0.39, so Haemonetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.39 |
| 52-Week Price Change | -14.09% |
| 50-Day Moving Average | 81.12 |
| 200-Day Moving Average | 82.88 |
| Relative Strength Index (RSI) | 31.79 |
| Average Volume (20 Days) | 533,607 |
Short Selling Information
The latest short interest is 4.57 million, so 9.09% of the outstanding shares have been sold short.
| Short Interest | 4.57M |
| Short Previous Month | 5.16M |
| Short % of Shares Out | 9.09% |
| Short % of Float | 9.19% |
| Short Ratio (days to cover) | 6.33 |
Income Statement
In the last 12 months, Haemonetics had revenue of $1.36 billion and earned $123.81 million in profits. Earnings per share was $2.41.
| Revenue | 1.36B |
| Gross Profit | 753.35M |
| Operating Income | 232.52M |
| Pretax Income | 146.99M |
| Net Income | 123.81M |
| EBITDA | 333.44M |
| EBIT | 232.52M |
| Earnings Per Share (EPS) | $2.41 |
Balance Sheet
The company has $300.03 million in cash and $1.31 billion in debt, giving a net cash position of -$1.01 billion or -$20.21 per share.
| Cash & Cash Equivalents | 300.03M |
| Total Debt | 1.31B |
| Net Cash | -1.01B |
| Net Cash Per Share | -$20.21 |
| Equity (Book Value) | 878.85M |
| Book Value Per Share | 17.44 |
| Working Capital | 681.96M |
Cash Flow
In the last 12 months, operating cash flow was $84.94 million and capital expenditures -$53.82 million, giving a free cash flow of $31.12 million.
| Operating Cash Flow | 84.94M |
| Capital Expenditures | -53.82M |
| Free Cash Flow | 31.12M |
| FCF Per Share | $0.62 |
Margins
Gross margin is 55.34%, with operating and profit margins of 17.08% and 9.10%.
| Gross Margin | 55.34% |
| Operating Margin | 17.08% |
| Pretax Margin | 11.67% |
| Profit Margin | 9.10% |
| EBITDA Margin | 24.50% |
| EBIT Margin | 17.08% |
| FCF Margin | 2.29% |
Dividends & Yields
Haemonetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.23% |
| Shareholder Yield | -0.23% |
| Earnings Yield | 3.27% |
| FCF Yield | 0.82% |
Analyst Forecast
The average price target for Haemonetics is $108.78, which is 44.19% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $108.78 |
| Price Target Difference | 44.19% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 8.77% |
| EPS Growth Forecast (5Y) | 35.09% |
Stock Splits
The last stock split was on December 3, 2012. It was a forward split with a ratio of 2:1.
| Last Split Date | Dec 3, 2012 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Haemonetics has an Altman Z-Score of 2.92 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.92 |
| Piotroski F-Score | 5 |